By Christopher P. Singer --
In a December 19, 2006 press release, Pfizer Inc.
announced that its Australian patent AU 601,981 covering atorvastatin (the
active ingredient in Lipitor®) was upheld by the Australian Federal Court in
Victoria. The ruling concluded Ranbaxy's 2005 lawsuit and imposes an injunction
against Ranbaxy's generic product. The
601,981 patent is in effect through May 2012.
The court ruled against Pfizer concerning its AU 628,198
patent covering the atorvastatin calcium salt, holding that patent to be
invalid.
Each decision can be appealed.
Comments